Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.

Matos JP, de Lourdes Rodrigues M, Ismerim VL, Boasquevisque EM, Genelhu V, Francischetti EA.

Clin Nephrol. 2005 Sep;64(3):180-9.

PMID:
16175942
2.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
3.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
4.
6.

Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.

Dalla Vestra M, Simioni N, Masiero A.

Int Urol Nephrol. 2009;41(1):119-26. doi: 10.1007/s11255-008-9490-0. Epub 2008 Oct 29. Review.

PMID:
18958580
7.
8.

Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.

Hollenberg NK.

J Hypertens Suppl. 1997 Dec;15(7):S7-13. Review.

PMID:
9532515
9.

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Reboldi G, Gentile G, Angeli F, Verdecchia P.

Vasc Health Risk Manag. 2009;5(1):411-27. Review.

10.

An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.

García-Donaire JA, Segura J, Ruilope LM.

Expert Opin Pharmacother. 2005 Aug;6(9):1587-96. Review.

PMID:
16086646
11.
12.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
13.

Angiotensin blockade in type 2 diabetic renal disease.

Ruilope LM, Luño J.

Kidney Int Suppl. 2002 Dec;(82):S61-3. Review.

14.

The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Ruggenenti P, Cravedi P, Remuzzi G.

Nat Rev Nephrol. 2010 Jun;6(6):319-30. doi: 10.1038/nrneph.2010.58. Epub 2010 May 4. Review.

PMID:
20440277
15.

Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.

Eberhard R, Dikow R.

Ann Med. 2002;34(7-8):507-13. Review.

PMID:
12553490
16.

Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Croom KF, Plosker GL.

Drugs. 2008;68(11):1543-69. Review.

PMID:
18627212
17.

Outcome studies in diabetic nephropathy.

Mohanram A, Toto RD.

Semin Nephrol. 2003 May;23(3):255-71. Review.

PMID:
12838494
18.

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.

PMID:
17877649
19.

Limitations of angiotensin inhibition.

Nobakht N, Kamgar M, Rastogi A, Schrier RW.

Nat Rev Nephrol. 2011 Jun;7(6):356-9. doi: 10.1038/nrneph.2011.29. Epub 2011 Apr 19. Review.

PMID:
21502972
20.

Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.

Feng YH, Fu P.

Chin Med J (Engl). 2016 Jan 5;129(1):81-7. doi: 10.4103/0366-6999.172599. Review.

Supplemental Content

Support Center